Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial

Title
Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial
Author(s)
문기학고영휘Sae Woong Kim[Sae Woong Kim]Du Geon Moon[Du Geon Moon]Je Jong Kim[Je Jong Kim]Nam Cheol Park[Nam Cheol Park]Sung Won Lee[Sung Won Lee]Jae-Seung Paick[Jae-Seung Paick]Tae Young Ahn[Tae Young Ahn]Woo Sik Chung[Woo Sik Chung]Kwon Sik Min[Kwon Sik Min]Jong Kwan Park[Jong Kwan Park]Dae Yul Yang[Dae Yul Yang]Kwangsung Park[Kwangsung Park]
Keywords
PHOSPHODIESTERASE TYPE-5 INHIBITOR; TADALAFIL 5 MG; DOUBLE-BLIND; PDE5 INHIBITOR; RAT MODEL; A-DAY; SAFETY; DA-8159; MEN
Issue Date
201505
Publisher
WILEY-BLACKWELL
Citation
JOURNAL OF SEXUAL MEDICINE, v.12, no.5, pp.1194 - 1201
Abstract
IntroductionThe method of administration of oral phosphodiesterase-5 inhibitors has been expanded to once-daily repeated administration with lower initial dosage than on-demand administration. AimThe aim of this study was to evaluate the efficacy and safety of once-daily udenafil as a treatment for erectile dysfunction (ED) for intermediate-term period. MethodsThis multicenter, randomized, double-blind clinical trial included 346 ED patients (placebo, udenafil 50mg, udenafil 75mg). Subjects were treated with each medication once daily for 24 weeks. Main Outcome MeasuresSubjects were asked to complete the International Index of Erectile Function (IIEF)-erectile function (EF) domain at baseline, 12 weeks, and 24 weeks and the development of adverse drug reactions (ADRs) was inspected. ResultsBoth dosages of udenafil induced a significant increase in IIEF-EF compared with placebo at both 12 and 24 weeks. When patients were divided according to the severity of baseline EF score, significant improvement was observed only with udenafil 75mg regardless of the degree of ED. At 24 weeks, the proportions of patients who reported a return to normal EF (IIEF-EF over 26) were 39.1% for udenafil 50mg and 47.0% for udenafil 75mg. In terms of safety, ADRs were observed in 6.1%, 12.9%, and 17.9% for placebo, udenafil 50mg, and 75mg, respectively. Although a statistically higher rate of ADRs was observed in the udenafil 75mg group (P=0.024), the majority were mild and recovered without treatment. ConclusionsOnce-daily administration of udenafil 50mg and 75mg for 24 weeks resulted in improvement of EF. In particular, udenafil 75mg improves EF regardless of the baseline degree of ED. Moon KH, Ko YH, Kim SW, Moon DG, Kim JJ, Park NC, Lee SW, Paick J-S, Ahn TY, Chung WS, Min KS, Park JK, Yang DY, and Park K. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: Results from a randomized multicenter placebo-controlled clinical trial. J Sex Med 2015;12:1194-1201.
URI
http://hdl.handle.net/YU.REPOSITORY/32494http://dx.doi.org/10.1111/jsm.12862
ISSN
1743-6095
Appears in Collections:
의과대학 > 비뇨기과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE